Plain-English translation of NCT06915246 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lymphoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new version of the chemotherapy drug carmustine (called ) compared to the standard formulation (called ) in people with lymphoma who are receiving a stem cell transplant. Both versions are used as part of the conditioning regimen—the intense chemotherapy given before the transplant to prepare your body. The trial wants to see if the new formulation works just as well and may have fewer side effects.
Stem cell transplants can help cure lymphoma, but the conditioning chemotherapy before the transplant is very strong and can cause serious side effects. This trial is exploring whether a different formulation of the medication might be safer or easier to tolerate while still being effective.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of two versions of the chemotherapy drug as part of your conditioning regimen before your stem cell transplant. The conditioning treatment is delivered over several days in the hospital, and you will then receive your own stem cells back to help your bone marrow recover. You will be monitored closely during and after the transplant with blood tests, scans, and clinic visits to track your recovery and any side effects.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States